1. Home
  2. PCRX vs QSI Comparison

PCRX vs QSI Comparison

Compare PCRX & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • QSI
  • Stock Information
  • Founded
  • PCRX 2006
  • QSI 2013
  • Country
  • PCRX United States
  • QSI United States
  • Employees
  • PCRX N/A
  • QSI N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • QSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • PCRX Health Care
  • QSI Health Care
  • Exchange
  • PCRX Nasdaq
  • QSI Nasdaq
  • Market Cap
  • PCRX 1.2B
  • QSI 219.8M
  • IPO Year
  • PCRX 2011
  • QSI N/A
  • Fundamental
  • Price
  • PCRX $23.22
  • QSI $2.11
  • Analyst Decision
  • PCRX Buy
  • QSI Strong Buy
  • Analyst Count
  • PCRX 8
  • QSI 3
  • Target Price
  • PCRX $28.38
  • QSI $2.38
  • AVG Volume (30 Days)
  • PCRX 569.8K
  • QSI 8.4M
  • Earning Date
  • PCRX 07-29-2025
  • QSI 08-06-2025
  • Dividend Yield
  • PCRX N/A
  • QSI N/A
  • EPS Growth
  • PCRX N/A
  • QSI N/A
  • EPS
  • PCRX N/A
  • QSI N/A
  • Revenue
  • PCRX $702,772,000.00
  • QSI $3,443,000.00
  • Revenue This Year
  • PCRX $7.54
  • QSI $77.57
  • Revenue Next Year
  • PCRX $10.78
  • QSI $251.34
  • P/E Ratio
  • PCRX N/A
  • QSI N/A
  • Revenue Growth
  • PCRX 3.08
  • QSI 167.94
  • 52 Week Low
  • PCRX $11.16
  • QSI $0.61
  • 52 Week High
  • PCRX $27.64
  • QSI $5.77
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 35.42
  • QSI 65.03
  • Support Level
  • PCRX $22.82
  • QSI $1.87
  • Resistance Level
  • PCRX $24.36
  • QSI $2.14
  • Average True Range (ATR)
  • PCRX 0.69
  • QSI 0.14
  • MACD
  • PCRX -0.12
  • QSI 0.02
  • Stochastic Oscillator
  • PCRX 17.09
  • QSI 93.65

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.

Share on Social Networks: